Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia
- PMID: 30514883
- PMCID: PMC6462044
- DOI: 10.1038/s41386-018-0278-3
Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia
Abstract
Although some studies have suggested that relapse may be associated with antipsychotic treatment resistance in schizophrenia, the number and quality of studies is limited. The current analysis included patients with a diagnosis of first-episode schizophrenia or schizoaffective disorder who met the following criteria: (1) referral to the First-Episode Psychosis Program between 2003 and 2013; (2) treatment with an oral second-generation antipsychotic according to a standardized treatment algorithm; (3) positive symptom remission; (4) subsequent relapse (i.e., second episode) in association with non-adherence; and (5) reintroduction of antipsychotic treatment with the same agent used to achieve response in the first episode. The following outcomes were used as an index of antipsychotic treatment response: changes in the brief psychiatric rating scale (BPRS) total and positive symptom scores and number of patients who achieved positive symptom remission and 20 and 50% response. A total of 130 patients were included in the analyses. Although all patients took the same antipsychotic in both episodes, there were significant episode-by-time interactions for all outcomes of antipsychotic treatment response over 1 year in favor of the first episode compared to the second episode (50% response rate: 48.7 vs. 10.4% at week 7; 88.2 vs. 27.8% at week 27, respectively). Although antipsychotic doses in the second episode were significantly higher than those in the first episode, results remained unchanged after adjusting for antipsychotic dose. The present findings suggest that antipsychotic treatment response is reduced or delayed in the face of relapse following effective treatment of the first episode of schizophrenia.
Figures
Similar articles
-
Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.Arch Gen Psychiatry. 1999 Mar;56(3):241-7. doi: 10.1001/archpsyc.56.3.241. Arch Gen Psychiatry. 1999. PMID: 10078501
-
Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study.J Clin Psychiatry. 2016 Apr;77(4):492-500. doi: 10.4088/JCP.14m09540. J Clin Psychiatry. 2016. PMID: 26759992
-
Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.Clin Ther. 2008 Dec;30(12):2378-86. doi: 10.1016/j.clinthera.2008.12.020. Clin Ther. 2008. PMID: 19167596
-
Atypical antipsychotics for psychosis in adolescents.Cochrane Database Syst Rev. 2013 Oct 15;(10):CD009582. doi: 10.1002/14651858.CD009582.pub2. Cochrane Database Syst Rev. 2013. PMID: 24129841 Review.
-
Beyond Clinical Remission in First Episode Psychosis: Thoughts on Antipsychotic Maintenance vs. Guided Discontinuation in the Functional Recovery Era.CNS Drugs. 2016 May;30(5):357-68. doi: 10.1007/s40263-016-0331-x. CNS Drugs. 2016. PMID: 27106296 Review.
Cited by
-
Lessons from studies of medication reduction in psychosis: giving participants accurate information about risk in psychiatric research trials.J Psychiatry Neurosci. 2024 Mar 1;49(2):E81-E86. doi: 10.1503/jpn.230137. Print 2024 Jan-Feb. J Psychiatry Neurosci. 2024. PMID: 38428969 Free PMC article.
-
Population Pharmacokinetic Analysis to Support and Facilitate Switching from Risperidone Formulations to Rykindo in Patients with Schizophrenia.Neurol Ther. 2024 Jan 20. doi: 10.1007/s40120-024-00578-w. Online ahead of print. Neurol Ther. 2024. PMID: 38244179
-
Psychosis superspectrum I: Nosology, etiology, and lifespan development.Mol Psychiatry. 2024 Jan 10. doi: 10.1038/s41380-023-02388-2. Online ahead of print. Mol Psychiatry. 2024. PMID: 38200290 Review.
-
Symptomatic, functional and quality of life measures of remission in 194 outpatients with schizophrenia followed naturalistically in a 6-month, non-interventional study of aripiprazole once-monthly.Schizophrenia (Heidelb). 2023 Nov 8;9(1):80. doi: 10.1038/s41537-023-00405-5. Schizophrenia (Heidelb). 2023. PMID: 37935711 Free PMC article.
-
Antipsychotics and structural brain changes: could treatment adherence explain the discrepant findings?Ther Adv Psychopharmacol. 2023 Sep 8;13:20451253231195258. doi: 10.1177/20451253231195258. eCollection 2023. Ther Adv Psychopharmacol. 2023. PMID: 37701891 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
